In Vivo CAR-T Cell Therapy Services

Chimeric Antigen Receptor T cell (CAR-T) therapy has transformed the treatment landscape for cancer. Traditional ex vivo CAR-T approaches, while effective, are limited by high costs, long manufacturing timelines, and accessibility issues.

In vivo CAR-T is the next evolution—offering a transformative approach where CAR-T cells are generated directly inside the patient’s body. This eliminates the need for cell collection and laboratory modification, simplifying treatment and expanding patient access.

Key Advantages of In Vivo CAR-T

  • Off-the-shelf therapy – no need for personalized cell manufacturing

  • No lymphodepletion required

  • No risk of graft-versus-host disease (GvHD)

  • Reduced immune rejection of engineered cells

  • High scalability – treat hundreds of patients per production batch

  • Streamlined patient experience – simplified treatment workflow

  • Compatible with multiple cell types – T cells, NK cells, macrophages

  • Lower complexity and cost – bypasses ex vivo processing

Service Offerings

Non-Viral Platforms

  • Lipid Nanoparticle (LNP)–mRNA/Circular RNA

  • LNP–Bridge RNA

  • LNP–Transposon

  • Virus-Like Particles (VLPs)

Viral Platforms

  • Lentiviral Vectors (LV)

  • Adeno-Associated Virus (AAV)

Cell-Specific Targeting

  • CD3⁺ T cells

  • CD4⁺ and CD8⁺ T cell subsets

  • NK cells

  • Macrophages

Platform Enhancements

  • Fusogen mutant screening & discovery – for enhanced gene delivery

  • T cell–specific promoter optimization – to boost selective CAR expression

Why Choose RedyBio?

  • Industry-leading expertise in both non-viral (LNP-RNA) and viral CAR delivery systems

  • Deep experience in CAR design and optimization

  • Flexible and scalable platforms tailored to your therapeutic goals

Contact us

Our highly experienced scientists, and biotechnology service experts are here to assist you with all your drug development needs.